AccurKardia’s AccurECG Named “Best New Technology Solution for ECG” in 9th Annual MedTech Breakthrough Awards Program

NEW YORK–(BUSINESS WIRE)–AccurKardia, an innovator in ECG-based diagnostics technology, today announced that its AccurECG^TM software platform has been selected as winner of the “Best New Technology Solution for ECG” award in the 9^th annual MedTech Breakthrough Awards. The program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market.

AccurECG provides automated, near real-time beat-by-beat ECG analysis across multiple arrhythmias, including atrial fibrillation, atrial flutter, and other critical events.

Share

AccurECG⁽¹⁾ provides automated, near real-time beat-by-beat ECG analysis across multiple arrhythmias, including atrial fibrillation, atrial flutter, and other critical events. Device-agnostic and vendor neutral, the platform seamlessly integrates with diverse hardware including short duration recordings from ECG systems and multi-day Holter or patch monitors. AccurECG’s flexible API allows clinical and commercial partners to be swiftly integrated into existing workflows, reducing turnaround times and enhancing cardiac technicians’ capabilities in pinpointing dangerous cardiac arrhythmias and treating patients earlier.

Beyond AccurECG, AccurKardia is working to expand the use of ECGs as a broad biomarker. In 2024, AccurKardia received FDA Breakthrough Device Designations for two novel applications:

• AK-AVS^TM(2) – An ECG-based AI algorithm that screens for and enables early detection of moderate to severe Aortic Valve Stenosis, targeting a largely underdiagnosed yet life-threatening condition.
• AK+ Guard ^TM(2) – A Lead I ECG-based, AI-powered hyperkalemia detection tool designed for consumer and clinical wearables, which was also accepted into the FDA’s highly selective Total Product Life Cycle (TAP) program. This tool extends hyperkalemia detection outside of the clinic and helps to identify moderate to severe episodes of hyperkalemia (excess potassium in the blood) that can lead to sudden cardiac arrest.

“By pioneering these breakthrough ECG-based solutions, AccurKardia is redefining cardiac diagnostics—making them more accessible, actionable, and predictive, ultimately transforming how we detect, treat, and prevent life-threatening conditions,” said Steve Johansson, managing director, MedTech Breakthrough.

“We are grateful to MedTech Breakthrough for recognizing AccurECG as the ‘Best New Technology Solution for ECG,’” said Juan C. Jimenez, co-founder and CEO of AccurKardia. “We will continue to deliver innovative solutions that align with our mission to improve patient outcomes and save lives globally, transforming ECGs into a more powerful arrhythmia detection tool and broad biomarker for cardiology and beyond.”

The MedTech Breakthrough Awards program celebrates excellence and innovation in the health and medical technology industry, recognizing the companies, products, and solutions driving meaningful progress and improving patient care. Spanning a wide range of categories—including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data & Privacy, and beyond—the awards highlight the groundbreaking work that is transforming the healthcare landscape.

This year’s program saw a record-breaking number of nominations from leading companies and startups across more than 18 countries, showcasing the global impact and momentum of the digital healthcare industry today.

About AccurKardia

AccurKardia is an ECG-led diagnostics software company focused on transforming ECG data into a more powerful diagnostic tool and broad biomarker to improve patient outcomes and save lives globally. With initial applications in cardiology, the company offers transformative, cloud-based diagnostic tools, including AccurECG™, an FDA-cleared Class II software as a medical device (SaMD) for fully automated, near real-time ECG interpretation. AK+ Guard^TM, the Company’s Hyperkalemia AI-powered detection model via Lead I ECGs was accepted in FDA TAP Program and received Breakthrough Device Designation in December 2024. AccurKardia’s aortic stenosis AI-powered detection ECG model, AK-AVS™, received FDA Breakthrough Device Designation in October 2024. The company completed the 2024 Cohort of MedTech Innovator (MTI) and was one of five companies selected for the American Heart Association’s Heart and Brain Health Accelerator track within MTI. For more information, please visit www.accurkardia.com.

About MedTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.

Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.

Notes:

1. For detailed technical AccurECG requirements, relevant disclosures, and approved indications for use, please refer to the U.S. FDA 510(k) K223013 summary and product labeling.
2. AK-AVS and AK+ Guard are currently for research use only and have not been cleared or approved by the U.S. FDA for use in the United States. This technology is under development and intended solely for investigational purposes.